Deciphering the molecular basis of venous thromboembolism: where are we and where should we go?

被引：14
作者：
Morange, Pierre-Emmanuel [1 ]
Tregouet, David-Alexandre [2 ]
机构：
[1] Univ Mediterranean, Fac Med, INSERM, UMR S626, Marseille, France
[2] Univ Paris 06, INSERM, UMR S937, Paris, France
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2010年 / 148卷 / 04期
关键词：
genetics of thrombosis and haemostasis; epidemiology; venous thrombosis; GENOME-WIDE ASSOCIATION; VON-WILLEBRAND-FACTOR; FACTOR-V-LEIDEN; ACTIVATABLE FIBRINOLYSIS INHIBITOR; QUANTITATIVE-TRAIT LOCUS; FACTOR PATHWAY INHIBITOR; COMMON GENETIC-VARIATION; COPY NUMBER VARIATION; FACTOR-XII GENE; RISK-FACTOR;
D O I：
10.1111/j.1365-2141.2009.07975.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Venous thromboembolism (VTE) is a frequent disease that has a major genetic component of risk. However, known identified genetic risk factors account for <30% of idiopathic (without any environmental origin) VTE cases. This article aims to review the lessons learnt during recent decades in the field of the genetics of VTE, describe the present state-of-art methods and discuss promising themes for finding new susceptibility loci.
引用
收藏
页码：495 / 506
页数：12
相关论文
共 50 条
  • [41] MRSA in Humans, Pets and Livestock in Portugal: Where We Came from and Where We Are Going
    Silva, Vanessa
    Monteiro, Andreia
    Pereira, Jose Eduardo
    Maltez, Luis
    Igrejas, Gilberto
    Poeta, Patricia
    PATHOGENS, 2022, 11 (10):
  • [42] Cell surface membrane proteins as personalized biomarkers: where we stand and where we are headed
    Varady, Gyoergy
    Cserepes, Judit
    Nemeth, Adrienn
    Szabo, Edit
    Sarkadi, Balazs
    BIOMARKERS IN MEDICINE, 2013, 7 (05) : 803 - 819
  • [43] Venous thromboembolism in childhood: where is Brazil after 20 years?
    Mello, Tayana Teixeira
    Carneiro, Jorge David Aivazoglou
    Mello, Guilherme Arantes
    Bizzacchi, Joyce Maria Annichinno
    HEMATOLOGY TRANSFUSION AND CELL THERAPY, 2020, 42 (01) : 62 - 69
  • [44] Breast Implant Surfaces and Their Impact on Current Practices: Where We Are Now and Where Are We Going?
    Munhoz, Alexandre Mendonca
    Clemens, Mark W.
    Nahabedian, Maurice Y.
    PLASTIC AND RECONSTRUCTIVE SURGERY-GLOBAL OPEN, 2019, 7 (10) : E2466
  • [45] Vitamin D and multiple sclerosis: where do we go from here?
    Salzer, Jonatan
    Bistrom, Martin
    Sundstrom, Peter
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2014, 14 (01) : 9 - 18
  • [46] Epidemiologic studies of childhood leukemia: Where do we go from here?
    Ross, JA
    MEDICAL AND PEDIATRIC ONCOLOGY, 1999, 32 (01): : 65 - 67
  • [47] Overview of the relationship between pain and obesity: What do we know? Where do we go next?
    Janke, E. Amy
    Collins, Allison
    Kozak, Andrea T.
    JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT, 2007, 44 (02) : 245 - 261
  • [48] Eating disorder risk in rural US adolescents: What do we know and where do we go?
    Hahn, Samantha L.
    Burnette, C. Blair
    Borton, Kelley A.
    Carpenter, Lisa Mitchell
    Sonneville, Kendrin R.
    Bailey, Beth
    INTERNATIONAL JOURNAL OF EATING DISORDERS, 2023, 56 (02) : 366 - 371
  • [49] Prediction of spontaneous preterm delivery in singleton pregnancies: Where are we and where are we going? A review of literature
    Sananes, N.
    Langer, B.
    Gaudineau, A.
    Kutnahorsky, R.
    Aissi, G.
    Fritz, G.
    Boudier, E.
    Viville, B.
    Nisand, I.
    Favre, R.
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2014, 34 (06) : 457 - 461
  • [50] Recommended care received by geriatric hip fracture patients: where are we now and where are we heading?
    Seys, Deborah
    Sermon, An
    Sermeus, Walter
    Panella, Massimiliano
    Bruyneel, Luk
    Boto, Paulo
    Vanhaecht, Kris
    ARCHIVES OF ORTHOPAEDIC AND TRAUMA SURGERY, 2018, 138 (08) : 1077 - 1087
12345